Litigation Details for Transmeta Corporation v. Intel Corporation (D. Del. 2006)

Transmeta Corporation v. Intel Corporation (D. Del. 2006)

Docket		Date Filed	2006-10-11
Court	District Court, D. Delaware	Date Terminated	2008-02-01
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Both	Referred To
Parties	INTEL CORPORATION
Patents	10,047,097
Attorneys	Karen Elizabeth Keller
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Transmeta Corporation v. Intel Corporation (D. Del. 2006)

Date Filed	Document No.	Description	Snippet	Link To Document
2006-10-11				External link to document

Transmeta Corporation v. Intel Corporation (1:06-cv-00633): Litigation Summary, Case Posture, and IP/Exclusivity Implications

Last updated: May 22, 2026

Transmeta v. Intel (N.D. California, case no. 1:06-cv-00633) is a patent-focused dispute that turned on alleged infringement involving Transmeta’s energy-efficient microprocessor technologies and Intel’s x86-compatible processor products. The action’s commercial and strategic impact is tied to how courts treated the asserted patents and claim scope, and how that treatment shaped subsequent licensing, settlement posture, and the feasibility of generic-style “design-around” strategies for competitors.

What patents were asserted in Transmeta v. Intel (1:06-cv-00633)?

Answer: The litigation centers on Transmeta’s microarchitecture/power-management patent portfolio directed to low-power computing and related CPU techniques, with Intel accused for incorporating comparable concepts in x86 processors.

Which Transmeta technology themes appear in the asserted claims?

Featured claim clusters in Transmeta-era processor litigation typically map to three technical buckets that drove infringement arguments in these cases:

• Power consumption reduction via hardware state control and power gating concepts
• Efficient execution through dynamic translation/translation-like behavior (depending on the specific patent)
• Performance/power balancing mechanisms in CPU microarchitectures

How did the court likely frame claim scope in this technology class?

In microprocessor disputes of this era, courts commonly construe:

• Terms tied to “translation,” “instruction conversion,” and intermediate representations (if asserted)
• Limitations describing specific microarchitectural steps or state transitions
• Method versus system claim boundaries, and whether alleged “steps” exist across multiple components

Impact for Intel: If claim construction narrowed the asserted limitations, Intel’s design-around and noninfringement arguments gained traction. If construction broadened claims, Intel’s invalidity defenses (anticipation/obviousness) typically became more central.

What was the litigation posture and procedural timeline in 1:06-cv-00633?

Answer: The case progressed through typical patent litigation phases: complaint, responsive pleadings, claim construction, dispositive motions, and either trial outcomes or case resolution through settlement or dismissal.

Key procedural milestones to track

For patent cases at this docket number range, the decision and filings cadence usually follows:

• Early infringement/noninfringement and invalidity allegations tied to specific Intel CPUs and/or platforms
• Markman (claim construction) affecting claim interpretation
• Potential summary judgment addressing noninfringement and/or invalidity
• Final disposition by judgment, dismissal, or settlement

Why the claim-construction stage matters

In microprocessor patent litigation, claim construction often drives the practical case value because it:

• Determines whether Intel’s “implementation” aligns with the literal limitations
• Alters the assessment of equivalence (if doctrine-of-equivalents issues are pursued)
• Controls what technical evidence becomes material at summary judgment and trial

How did the court treat infringement and noninfringement in Transmeta v. Intel?

Answer: The infringement analysis depended on whether Intel’s accused processor functionality met all asserted claim limitations under the court’s constructions.

Noninfringement pathways that typically decide these disputes

Intel’s most common defenses in similar CPU IP cases include:

• Claim construction defeats “translation-like” or “power-state” mappings
• Missing required steps or missing required hardware components
• Partitioning of functionality across system layers such that method claims fail

What technical evidence usually becomes determinative

Evidence typically includes:

• Patent claim charts (with step-by-step mapping)
• CPU microarchitecture documentation and expert testimony
• “Accused product” characterization and performance/power state behavior
• Source-level or microcode evidence where available

Which invalidity defenses mattered most in 1:06-cv-00633?

Answer: Invalidity generally centers on anticipation and obviousness, with prior art in CPU power management and dynamic instruction handling being the key categories.

Prior art themes that often undermine these patents

• Existing low-power processor techniques predating the priority dates
• Known power-management circuits and operating state controls
• Prior dynamic translation and instruction transformation mechanisms

What happens if invalidity is sustained

If the court invalidated one or more core asserted claims:

• It can eliminate key infringement leverage
• It can reduce settlement value if surviving claims are limited
• It can push the litigation toward dismissal or narrower continuing claims

What patent validity outcomes affected the business value of Transmeta’s portfolio?

Answer: The business value turns on whether at least one asserted claim survived construction and invalidity scrutiny.

Portfolio survivability and licensing leverage

• Surviving claims strengthen licensing threats and make settlement more likely
• If all asserted claims fall, patent estate leverage collapses, and future enforcement becomes less credible

Freedom-to-operate impact for Intel

Even without a full invalidity ruling:

• Narrow construction can create practical noninfringement
• Dispositive noninfringement can reduce the risk premium for Intel’s processor roadmap

Did Transmeta win any judgment, or was the case resolved via settlement?

Answer: The docket indicates a resolved action rather than an enduring, fully litigated end-stage remedies posture. The case’s final disposition is the primary determinant of whether any asserted claims were upheld through judgment.

What to focus on in the final disposition

• Whether the disposition was with prejudice (final) or without prejudice (renewable)
• Whether any consent judgments or covenants were entered
• Whether any attorneys’ fees shifting occurred under fee statutes

How does 1:06-cv-00633 affect current Intel product risk and design-around strategy?

Answer: This case affects risk by clarifying, through claim construction and dispositive rulings, how far Transmeta’s asserted limitations extend to modern processor implementations.

Practical outcomes of “narrowing”

If the court narrowed key terms:

• Intel and other x86 suppliers can design around by avoiding specific state-machine steps or intermediate-stage behaviors that map to the patents’ limited constructions

Practical outcomes of “broadening”

If the court broadened terms:

• Potential exposure shifts to other implementations that resemble those broader limitations
• Competitors may need to evaluate equivalence arguments more carefully

How strong is the Transmeta patent estate implicated by this litigation?

Answer: The strength is measured by survivability of asserted claims through construction and invalidity review, and by whether any final rulings created enforceable enforceability outcomes.

Strength indicators to extract from case results

• Count of asserted claims that survived
• Whether any survived claims were found infringed
• Whether the decision relied on technical limitations that map cleanly to specific implementation patterns

What other IP disputes or related cases did this litigation overlap with?

Answer: Transmeta’s licensing and CPU technology enforcement period commonly overlapped with multiple actions involving processor power optimization and instruction handling concepts across industry participants.

Why overlap matters

Overlap can:

• Reinforce claim constructions across cases
• Create consistency arguments if the same terms are asserted elsewhere
• Amplify settlement leverage if multiple courts adopt similar interpretations

What are the Orange Book and FDA relevance for 1:06-cv-00633?

Answer: None. This is not an FDA small-molecule or biologic regulatory exclusivity dispute; it is a patent infringement action involving microprocessor technology.

---

Case Data Table (Docket-Level)

Item	Value
Case name	Transmeta Corporation v. Intel Corporation
Docket number	1:06-cv-00633
Court	United States District Court (federal)
Subject matter	Patent infringement involving microprocessor technology
Primary legal issues	Claim construction, infringement, invalidity
Regulatory linkage	None (no Orange Book / FDA exclusivity implications)

---

Key Takeaways

• Transmeta v. Intel (1:06-cv-00633) is a CPU microarchitecture and power-management patent dispute where outcomes hinge on claim construction and whether Intel products meet all asserted limitations.
• The case’s practical effect on Intel risk comes from how construed terms map to Intel microarchitectural implementations and from any dispositive rulings on infringement or invalidity.
• FDA/Orange Book exclusivity frameworks do not apply; this is a pure patent enforcement matter.

FAQs

1. What is the significance of claim construction in patent suits like Transmeta v. Intel (1:06-cv-00633)?
2. Do Transmeta’s CPU patents typically face invalidity challenges based on prior art in power management and instruction handling?
3. How do courts evaluate method versus system claim infringement in microprocessor cases?
4. What does a noninfringement finding imply for competitor freedom-to-operate in similar processor architectures?
5. How can settlement or dismissal in 1:06-cv-00633 affect future Transmeta enforcement against other semiconductor vendors?

References

1. PACER / U.S. District Court docket for Transmeta Corporation v. Intel Corporation, 1:06-cv-00633.